Xiao-Yan Li

Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn’s Disease

Background Infliximab (IFX), a cornerstone anti-TNF-α therapy for moderate-to-severe Crohn’s disease (CD), is limited by secondary loss of response (SLOR), yet existing prognostic tools lack sufficient accuracy and interpretability. We developed and internally validated an interpretable machine learning (ML) framework...